Neurogene (NGNE) Equity Average (2014 - 2026)

Neurogene has reported Equity Average for 13 years, with the latest figure at $251.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 16.52% year-over-year to $251.3 million; the trailing twelve-month figure through Mar 2026 stood at $251.3 million (down 16.52% YoY), and the FY2025 full-year result was $287.6 million, up 15.89% from the prior year.
• Equity Average for Q1 2026 stood at $251.3 million, down from $265.2 million in the prior quarter.
• The five-year high for Equity Average was $301.1 million in Q1 2025, with the low at -$176.1 million in Q3 2023.
• Historically, Equity Average has averaged $107.3 million across 5 years, with a median of $146.2 million in 2024.
• Annual changes were most pronounced in 2023 — Equity Average slumped 893.7% — and 2024, when it surged 15807.25%.
• Neurogene's Equity Average stood at -$20.0 million in 2022, then soared by 107.02% to $1.4 million in 2023, then surged by 15807.25% to $223.9 million in 2024, then gained by 18.45% to $265.2 million in 2025, then slipped by 5.23% to $251.3 million in 2026.
• The last three Equity Average figures came in at $251.3 million (Q1 2026), $265.2 million (Q4 2025), and $269.4 million (Q3 2025), per Business Quant data.